Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 46-57

  Duong, Connie P M ^a,b   Yong, Carmen S M ^a,b   Kershaw, Michael H ^a,b,c   Slaney, Clare Y ^a,b   Darcy, Phillip K ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Adoptive immunotherapy; Chimeric antigen receptor; T cell receptor; Tumor infiltrating lymphocytes

Indexed keywords

CANCER TESTIS ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; IMMUNOMODULATING AGENT; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER THERAPY; CAUSE OF DEATH; CELL ISOLATION; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DISEASE ASSOCIATION; DNA MODIFICATION; HEALTH CARE QUALITY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PROCEDURES; TRANSGENE; TRANSLATIONAL RESEARCH; TRANSPLANTATION; TREATMENT OUTCOME; TRENDS;

HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MODELS, IMMUNOLOGICAL; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; TRANSGENES; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84935843647     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.12.009     Document Type: Review

References (173)

1. Aebersold P., et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 1991, 83(13):932-937.
2. Anurathapan U., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther. 2014, 22(3):623-633.
3. Barrow C., et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin. Cancer Res. 2006, 12(3 Pt 1):764-771.
4. Barth R.J., et al. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 1991, 173(3):647-658.
5. Baxevanis C.N., et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994, 74(4):1275-1282.
6. Beavis P.A., et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(36):14711-14716.
7. Bendle G.M., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 2010, 16(5):565-570. 1p following 570.
8. Berger C., et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006, 107(6):2294-2302.
9. Besser M.J., et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010, 16(9):2646-2655.
10. Bevan M.J. Helping the CD8(+) T-cell response. Nat. Rev. Immunol. 2004, 4(8):595-602.
11. Bonini C., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276(5319):1719-1724.
12. Bouet-Toussaint F., et al. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur. Cytokine Netw. 2000, 11(2):217-224.
13. Brentjens R.J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118(18):4817-4828.
14. Brentjens R.J., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 2013, 5(177):177ra38.
15. Bubenik J. MHC class I down-regulation: tumour escape from immune surveillance? (review). Int. J. Oncol. 2004, 25(2):487-491.
16. Budde L.E., et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLOS ONE 2013, 8(12):e82742.
17. Burns W.R., et al. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009, 114(14):2888-2899.
18. Cameron B.J., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 2013, 5(197):197ra103.
19. Chang H.C., et al. A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. Proc. Natl. Acad. Sci. U. S. A. 1994, 91(24):11408-11412.
20. Chen Y.T., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(5):1914-1918.
21. Chinnasamy N., et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 2011, 186(2):685-696.
22. Clay T.M., et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol. 1999, 163(1):507-513.
23. Clemente C.G., et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77(7):1303-1310.
24. Cohen C.J., et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006, 66(17):8878-8886.
25. Cohen C.J., et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007, 67(8):3898-3903.
26. Coiffier B., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346(4):235-242.
27. Cole D.J., et al. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 1995, 55(4):748-752.
28. Connor M.E., Stern P.L. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer 1990, 46(6):1029-1034.
29. Craddock J.A., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 2010, 33(8):780-788.
30. Cui Y., et al. OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS ONE 2008, 3(8):e2990.
31. Davila M.L., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 2014, 6(224):224ra25.
32. Davis J.L., et al. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clin. Cancer Res. 2010, 16(23):5852-5861.
33. Deaglio S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204(6):1257-1265.
34. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365(18):1673-1683.
35. Dudley M.E., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298(5594):850-854.
36. Dudley M.E., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 2005, 23(10):2346-2357.
37. Dudley M.E., et al. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 2010, 16(24):6122-6131.
38. Duong C.P., et al. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 2011, 3(1):33-48.
39. Duval L., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin. Cancer Res. 2006, 12(4):1229-1236.
40. Eshhar Z., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. 1993, 90(2):720-724.
41. Fedorov V.D., Themeli M., Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 2013, 5(215):215ra172.
42. Figlin R.A., et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J. Urol. 1997, 158(3 Pt. 1):740-745.
43. Figlin R.A., et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 1999, 17(8):2521-2529.
44. Forni G., et al. Tumour inhibition by interleukin-2 at the tumour/host interface. Biochim. Biophys. Acta 1986, 865(3):307-327.
45. Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207(10):2175-2186.
46. Freedman R.S., et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J. Immunol. Methods 1994, 167(1-2):145-160.
47. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12(4):253-268.
48. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14(10):1014-1022.
49. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313(5795):1960-1964.
50. Gattinoni L., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202(7):907-912.
51. Gattinoni L., et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 2005, 115(6):1616-1626.
52. Gattinoni L., et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 2011, 17(10):1290-1297.
53. Gehring A.J., et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J. Hepatol. 2011, 55(1):103-110.
54. Gill S., et al. Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood 2014, 123(15):2343-2354.
55. Goydos J.S., Patel M., Shih W. NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J. Surg. Res. 2001, 98(2):76-80.
56. Grupp S.A., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368(16):1509-1518.
57. He C., et al. The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival. Clin. Dev. Immunol. 2011, 2011:p695834.
58. Hill G.R., et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997, 90(8):3204-3213.
59. Hinrichs C.S., et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(41):17469-17474.
60. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
61. Hoyos V., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24(6):1160-1170.
62. Huang C.T., et al. Role of LAG-3 in regulatory T cells. Immunity 2004, 21(4):503-513.
63. Iannone R., et al. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 2014, 4(2):172-181.
64. Introna M., et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum. Gene Ther. 2000, 11(4):611-620.
65. John L.B., et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 2013, 19(20):5636-5646.
66. Johnson L.A., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114(3):535-546.
67. Jurgens L.A., et al. Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: a novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma. J. Clin. Immunol. 2006, 26(1):22-32.
68. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2002, 2(4):251-262.
69. Kalos M., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3(95):95ra73.
70. Kandalaft L.E., Powell D.J., Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J. Transl. Med. 2012, 10:157.
71. Kawakami Y., Rosenberg S. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 1997, 14.
72. Kawakami Y., et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 1995, 154(8):3961-3968.
73. Kershaw M., et al. The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumors. J. Leukoc. Biol. 1996, 60(6):721-728.
74. Kershaw M.H., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12(20 Pt. 1):6106-6115.
75. Kershaw M.H., Westwood J.A., Darcy P.K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 2013, 13(8):525-541.
76. Kieback E., et al. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(2):623-628.
77. Kienstra M.A., et al. Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 2003, 25(6):457-463.
78. Kieper W.C., et al. Recent immune status determines the source of antigens that drive homeostatic T cell expansion. J. Immunol. 2005, 174(6):3158-3163.
79. Klapper J.A., et al. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J. Immunol. Methods 2009, 345(1-2):90-99.
80. Klebanoff C.A., et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005, 26(2):111-117.
81. Klebanoff C.A., et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(27):9571-9576.
82. Klebanoff C.A., et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011, 17(16):5343-5352.
83. Kloss C.C., et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31(1):71-75.
84. Kochenderfer J.N., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116(20):4099-4102.
85. Kochenderfer J.N., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119(12):2709-2720.
86. Kuball J., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007, 109(6):2331-2338.
87. Lamers C.H., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24(13):e20-e22.
88. Lamers C.H., et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117(1):72-82.
89. Lamers C.H., et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 2013, 21(4):904-912.
90. Lee D.W., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2014, Epub ahead of print. http://dx.doi.org/10.1016/S0140-6736(14)61403-3.
91. Leen A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121(26):5113-5123.
92. Li Y., et al. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 2005, 23(3):349-354.
93. Linette G.P., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 2013, 122(6):863-871.
94. Loi S., et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J. Clin. Oncol. 2013, 31(7):860-867.
95. Loo D., et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res. 2012, 18(14):3834-3845.
96. Lotze M.T., Rosenberg S.A. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer. Immunobiology 1986, 172(3-5):420-437.
97. Louis C.U., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118(23):6050-6056.
98. Magner W.J., et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J. Immunol. 2000, 165(12):7017-7024.
99. Marin V., et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum. Gene Ther. Methods 2012, 23(6):376-386.
100. Maude S.L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371(16):1507-1517.
101. McLaughlin P., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16(8):2825-2833.
102. Mezzanzanica D., et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther. 1998, 5(6):401-407.
103. Moeller M., et al. Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 2005, 106(9):2995-3003.
104. Morgan R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129.
105. Morgan R.A., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18(4):843-851.
106. Morgan R.A., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 2013, 36(2):133-151.
107. Mulder W.M., et al. Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity. Cancer Immunol. Immunother. 1995, 41(5):293-301.
108. Ossendorp F., et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 1998, 187(5):693-702.
109. Park J.R., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 2007, 15(4):825-833.
110. Parkhurst M.R., et al. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 2009, 15(1):169-180.
111. Parkhurst M.R., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19(3):620-626.
112. Peng W., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012, 72(20):5209-5218.
113. Petrausch U., et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer 2012, 12:615.
114. Porter D.L., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011, 365(8):725-733.
115. Qasim W., et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells targeting HBsAg in a liver transplant patient. J. Hepatol. 2014, Epub ahead of print. http://dx.doi.org/10.1016/j.jhep.2014.10.001.
116. Quintarelli C., et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007, 110(8):2793-2802.
117. Rapoport A.P., et al. Adoptive transfer of gene-modified T-cells engineered to express high-affinity TCRs for cancer-testis antigens (CTAs) NY-ESO-1 or Lage-1, in MM patients post auto-SCT. ASH Annu. Meet. Abstr. 2010, 120(21):472.
118. Ridolfi L., Ridolfi R., Riccobon A., De Paola F., Petrini M., Stefanelli M., Flamini E., Ravaioli A., Verdecchia G.M., Trevisan G., Amadori D. Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study. J. Immunother. 2003, 26(2):156-162.
119. Ritchie D.S., et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 2013, 21(11):2122-2129.
120. Robbins P.F., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29(7):917-924.
121. Rosenberg S.A., Fox E., Churchill W.H. Spontaneous regression of hepatic metastases from gastric carcinoma. Cancer 1972, 29(2):472-474.
122. Rosenberg S., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988, 319(25):1676-1680.
123. Rosenberg S.A., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988, 319(25):1676-1680.
124. Rosenberg S.A., et al. Gene transfer into humans - immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 1990, 323(9):570-578.
125. Rosenberg S.A., et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8(4):299-308.
126. Rosenberg S.A., et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17(13):4550-4557.
127. Sakuishi K., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207(10):2187-2194.
128. Sato E., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(51):18538-18543.
129. Sato T., et al. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol. Ther. 2007, 15(5):962-970.
130. Savoldo B., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011, 121(5):1822-1826.
131. Scholten K.B., et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J. Transl. Med. 2011, 9:147.
132. Schwartzentruber D.J., et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J. Clin. Oncol. 1994, 12(7):1475-1483.
133. Serafini M., et al. Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Hum. Gene Ther. 2004, 15(1):63-76.
134. Shen X., et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 2007, 30(1):123-129.
135. Sigalotti L., et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin. Oncol. 2005, 32(5):473-478.
136. Singh H., et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLOS ONE 2013, 8(5):e64138.
137. Skov S., et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005, 65(23):11136-11145.
138. Smith K.A., et al. The functional relationship of the interleukins. J. Exp. Med. 1980, 151(6):1551-1556.
139. Smith K.A., Gilbride K.J., Favata M.F. Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells. Nature 1980, 287(5785):853-855.
140. Spychala J. Tumor-promoting functions of adenosine. Pharmacol. Ther. 2000, 87(2-3):161-173.
141. Stanislawski T., et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2001, 2(10):962-970.
142. Straathof K.C., et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005, 105(11):4247-4254.
143. Testa U., et al. Interleukin 2 in cancer therapy. Ann. Ist. Super. Sanita 1990, 26(3-4):283-334.
144. Tiberghien P., et al. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?. Blood 1994, 84(4):1333-1341.
145. Till B.G., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112(6):2261-2271.
146. Till B.G., et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012, 119(17):3940-3950.
147. Topalian S.L., et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J. Immunol. Methods 1987, 102(1):127-141.
148. Topalian S.L., et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 1988, 6(5):839-853.
149. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366(26):2443-2454.
150. Tran K.Q., et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 2008, 31(8):742-751.
151. Uhlen M., et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 2010, 28(12):1248-1250.
152. van Lier R.A., ten Berge I.J., Gamadia L.E. Human CD8(+) T-cell differentiation in response to viruses. Nat. Rev. Immunol. 2003, 3(12):931-939.
153. van Schalkwyk M.C., et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum. Gene Ther. Clin. Dev. 2013, 24(3):134-142.
154. Vogler I., et al. An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol. Ther. 2010, 18(7):1330-1338.
155. Walia V., et al. Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res. 2012, 25(2):155-170.
156. Wang L.X., et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res. 2010, 70(23):9591-9598.
157. Wang X., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011, 118(5):1255-1263.
158. Warren R.S., et al. Clinical studies of regional and systemic gene therapy with autologous CC49-z modified T cells in colorectal cancer metastatic to the liver. (Abstract, 7th International Conference on Gene Therapy of Cancer). Cancer Gene Ther. 1998, 5(6 Suppl.):S1-S2.
159. Weng N.P., et al. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(24):11091-11094.
160. Westwood J.A., et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(52):19051-19056.
161. Westwood J.A., et al. The Lewis-Y carbohydrate antigen is expressed by many human tumors and can serve as a target for genetically redirected T cells despite the presence of soluble antigen in serum. J. Immunother. 2009, 32(3):292-301.
162. Wilkie S., et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 2012, 32(5):1059-1070.
163. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369(2):122-133.
164. Wolfl M., et al. Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy. Cancer Immunol. Immunother. 2011, 60(2):173-186.
165. Wrzesinski C., et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 2010, 33(1):1-7.
166. Xue S.A., et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood 2005, 106(9):3062-3067.
167. Yannelli J.R., et al. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 1996, 65(4):413-421.
168. Yee C., et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 2000, 192(11):1637-1644.
169. Yeh S., et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology 2009, 116(5):981-989 e1.
170. Zhang Y., et al. Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat. Med. 2005, 11(12):1299-1305.
171. Zhao Y., et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 2009, 183(9):5563-5574.
172. Zhong X.S., et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 2010, 18(2):413-420.
173. Zhu C., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6(12):1245-1252.